ESMO Virtual Meeting, 17–22 September 2020

Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: initial results in patients with solid tumours

Nicolas Girard, Martin Wermke, Fabrice Barlesi, Dong-Wan Kim, François Ghiringhelli, Jaafar Bennouna, Thierry Lesimple, Enriqueta Felip, David Berz, Jong-Seok Lee, Harald Timotheus Landsteiner, Victoria Chen, Girish Jayadeva, Jürgen Alt, Björn Hackanson




Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.


NOTE: These compounds are investigational agents and have not been approved for use. The efficacy and safety of these investigational compounds have not been established.